# Efficacy of Letrozole in Recurrent Ovarian Cancer

> **NCT04421547** · PHASE3 · TERMINATED · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 86 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Letrozole 2.5mg
- **DRUG:** Standard single agent chemotherapy

## Key facts

- **NCT ID:** NCT04421547
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-22
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-04
- **Target enrollment:** 86 (ACTUAL)
- **Why stopped:** Logistical problems impacting the speed of enrolment
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421547, "Efficacy of Letrozole in Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04421547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*